These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 10114373)

  • 1. Fees for certifying insulin drugs--FDA. Interim rule; opportunity for public comment.
    Fed Regist; 1991 Oct; 56(193):50248-9. PubMed ID: 10114373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Removal of regulations regarding certification of drugs composed wholly or partly of insulin--FDA. Direct final rule.
    Fed Regist; 1998 May; 63(92):26694-9. PubMed ID: 10179341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Removal of regulations regarding certification of drugs composed wholly or partly of insulin; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 May; 63(92):26690-3. PubMed ID: 10179340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human drugs and biologics; determination that informed consent is NOT feasible or is contrary to the best interests of recipients; revocation of 1990 interim final rule; establishment of new interim final rule. Food and Drug Administration, HHS. Interim final rule; opportunity for public comment.
    Fed Regist; 1999 Oct; 64(192):54180-9. PubMed ID: 11010702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicare program; revisions to payment policies under the physician fee schedule for calendar year 2003 and inclusion of registered nurses in the personnel provision of the critical access hospital emergency services requirement for frontier areas and remote locations. Final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2002 Dec; 67(251):79965-80184. PubMed ID: 12510665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality mammography standards. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Direct final rule.
    Fed Regist; 1999 Jun; 64(116):32404-7. PubMed ID: 10558582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicare program; revisions to payment policies, five-year review of work relative value units, changes to the practice expense methodology under the physician fee schedule, and other changes to payment under part B; revisions to the payment policies of ambulance services under the fee schedule for ambulance services; and ambulance inflation factor update for CY 2007. Final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2006 Dec; 71(231):69623-70251. PubMed ID: 17171850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality standards and certification requirements for mammography facilities--FDA. Interim rule; opportunity for public comment.
    Fed Regist; 1994 Sep; 59(189):49808-13. PubMed ID: 10137648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Laboratory Improvement Act program fee collection--HCFA. Final rule with comment.
    Fed Regist; 1992 Feb; 57(40):7188-218. PubMed ID: 10170938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Removal of regulations regarding certification of antibiotic drugs; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 May; 63(91):26127-9. PubMed ID: 10179335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality standards and certification requirements for mammography facilities--FDA. Interim rule with request for comments.
    Fed Regist; 1993 Dec; 58(243):67565-72. PubMed ID: 10131225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CLIA program; fee schedule revision--HCFA. General notice with comment period.
    Fed Regist; 1997 Aug; 62(168):45815-21. PubMed ID: 10169844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of revisit user fee program for Medicare survey and certification activities. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2007 Sep; 72(181):53627-49. PubMed ID: 17886406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicare program; revisions to payment policies under the physician fee schedule, and other Part B payment policies for CY 2008; revisions to the payment policies of ambulance services under the ambulance fee schedule for CY 2008; and the amendment of the e-prescribing exemption for computer generated facsimile transmissions. Final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2007 Nov; 72(227):66221-578. PubMed ID: 18044032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revisions to the requirements applicable to blood, blood components, and source plasma. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Direct final rule.
    Fed Regist; 1999 Aug; 64(160):45366-74. PubMed ID: 10558597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical devices; Mammography Quality Standards Act of 1992; inspection fees--FDA. Notice.
    Fed Regist; 1998 Jan; 63(9):2245-8. PubMed ID: 10177337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicare program; revisions to payment policies under the physician fee schedule for calendar year 2005. Final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2004 Nov; 69(219):66235-915. PubMed ID: 15551493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicare program; revisions to payment policies and five-year review of and adjustments to the relative value units under the physician fee schedule for calendar year 2002. Final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2001 Nov; 66(212):55245-503. PubMed ID: 11760761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicare program; fee schedule for payment of ambulance services and revisions to the physician certification requirements for coverage of nonemergency ambulance services. Final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2002 Feb; 67(39):9099-135. PubMed ID: 11868577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amendment to examination and investigation sample requirements--FDA. Direct final rule.
    Fed Regist; 1998 Sep; 63(186):51297-9. PubMed ID: 10185810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.